Evidence map›Paper›PMID 41720920›Full record

ArticleActa pharmacologica Sinica2026

Discovery of vasodilatory effects of Na

Xue-Fei Dong, Xue-Jiao Jing, Zhen-Yu Tang, Sheng-Lan Huang, Jia-Ze Yin, Yuan Chen, Tao Guo, Bo Dong, Bin Li, Peng Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xue-Fei Dong *State Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Xue-Jiao Jing *State Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Zhen-Yu Tang *Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, 250012, China.
Sheng-Lan Huang *State Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Jia-Ze Yin *State Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Yuan ChenState Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Tao GuoState Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Bo DongDepartment of Cardiology, Emergency Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Bin LiDepartment of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Peng LiCollege of Pharmacy, Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang Medical University, Xinxiang, 453003, China.
Shuang-Xi WangState Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China. shuangxiwang@sdu.edu.cn.
Wen-Wu BaiState Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, 250012, China. baiwenwu@sdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The best way of treating vasospastic angina pharmacologically is to induce vasorelaxation under hypoxia only. We previously established a new method to quantify the contraction and relaxation of vascular smooth muscle cells (VSMCs) in real time. In the present study, we used this method to screen the effects of chemicals on VSMC dilation under normoxia, and we chose the chemicals with negative results as candidates. Next, we tested the effects of the candidates on VSMC dilation under hypoxia, and we found that cariporide and empagliflozin induced VSMC relaxation under hypoxia but not normoxia. Their effects on hypoxic VSMC relaxation were further confirmed in isolated carotid arteries. We demonstrated that treatment with cariporide (10 μM) or empagliflozin (5 μM) potently inhibited Na

Indexed as

Angina PectorisCoronary VasospasmGuanidinesSodium-Hydrogen Exchanger 1SulfonesVasodilationVasodilator AgentsAnimalsGlucosidesMaleMuscle, Smooth, VascularMyocytes, Smooth MuscleSwinecariporideGlucosidesGuanidinesSodium-Hydrogen Exchanger 1SulfonesVasodilator Agentsacute coronary syndromecariporideempagliflozinhypoxiaNa+/H+ exchanger 1 inhibitorvascular smooth muscle cell

Identifiers

PMID41720920
PMCPMC13197480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.